International Clinical Trial: Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07735104) titled 'Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia' on July 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Qilu Pharmaceutical Co., Ltd.

Condition: Cancer Cachexia Syndrome Cancer Cachexia

Intervention: Drug: QLS2319

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: September 1, 2026

Target S...